Download our whitepaper,
"Overcoming Challenges in Cutaneous Lupus Erythematosus Clinical Trials: Insights into Diagnosis, Safety, and Drug Development"
.png)
What's Inside:
- Key FDA-Approved Pivotal Endpoints for Cutaneous Lupus Erythematosus Clinical Trials.
- Optimizing Recruitment with Adaptive Trial Designs for Cutaneous Lupus Erythematosus.
- Comprehensive Analysis of FDA-Approved Cutaneous Lupus Erythematosus Drugs.
- How Diagnostic Criteria for Cutaneous Lupus Erythematosus Have Evolved and Impact Research.
- Overcoming Common Pitfalls in Cutaneous Lupus Erythematosus Clinical Trials.
- And additional insights to drive your trial's success.
Access your complimentary whitepaper today:
Cutaneous Lupus Erythematosus
Cutaneous lupus erythematosus (CLE) is a multifaceted autoimmune condition predominantly characterized by skin manifestations, which can occur independently or as part of systemic lupus erythematosus (SLE).
Encompassing acute, subacute, and chronic subtypes, CLE presents a spectrum of clinical features, including photosensitivity, distinctive rashes, and potential for scarring. While primarily affecting the skin, the disease may progress to systemic involvement in a subset of patients, necessitating comprehensive diagnostic and therapeutic strategies.
Our whitepaper provides an in-depth exploration of CLE, examining its pathophysiology, diagnostic criteria, epidemiology, and the latest advancements in therapeutic approaches.
At iNGENū, we are dedicated to advancing the understanding and treatment of Cutaneous Lupus Erythematosus. Through cutting-edge research and a patient-centered approach, our mission is to deliver innovative solutions that improve the lives of individuals and families impacted by this challenging condition.
Women are affected
3-6x
more often than men
Approximately
4
cases per 100,000 people annually
Most common between the ages of 20-50
Our clinical team has over
120
years of combined clinical trial experience